The current landscape of multiple myeloma treatment

Leukemia Research

Volumn 32, Issue SUPPL. 1, 2008, Pages

  Cavo, Michele ^a   Attal, Michel ^b   Gertz, Morie A ^c   Giralt, Sergio ^d   Ludwig, Heinz ^e   Morgan, Gareth J ^f   Anderson, Kenneth C ^g  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Wilhelminenspital   (Austria)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL FEATURE; DRUG MECHANISM; HUMAN; MONOTHERAPY; MORBIDITY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 54049117285     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(08)70002-X     Document Type: Article

References (0)